CJC-1295 DAC Cycle Guide

DAC Cycle Structure: Optimizing Dosage Duration for Sustained Results

CJC-1295 DAC's extended 6-8 day half-life fundamentally alters optimal cycle structure compared to pulsatile non-DAC protocols. Steady-state drug concentration is achieved by injection 3-4 (approximately day 18-24), creating delayed onset of peak efficacy compared to non-DAC's immediate peak. This delayed kinetics shifts optimal cycle architecture: DAC requires minimum 10-12 weeks to fully capitalize on accumulated steady-state effects, whereas non-DAC produces peak benefits starting week 1. Standard DAC protocol: 1-2 mg injected once or twice weekly for 12-16 weeks continuous, followed by 6-8 week complete break. Continuous versus pulsed cycling decisions differ from non-DAC: because DAC's half-life eliminates pulsatile benefits, "pulsing" DAC (on/off cycles within treatment phase) provides minimal additional benefit compared to continuous dosing. Most effective protocols maintain continuous DAC administration throughout the treatment window (12-16 weeks) rather than cycling within the cycle. This contrasts non-DAC protocols where dose pulsing (varying frequency) during treatment can manage desensitization.

Weekly Dosing Patterns: Single vs. Twice-Weekly Administration

Two primary DAC dosing frequency patterns exist: (1) Once weekly, single 2 mg injection per week (e.g., Monday 2 mg), or (2) Twice weekly, split dosing (e.g., Monday 1 mg + Thursday 1 mg, total 2 mg weekly). Once-weekly protocols: maximum simplicity and compliance, single injection per week. Requires perfect needle technique (intramuscular or subcutaneous); single missed injection produces minimal effect due to extended half-life. Twice-weekly protocols: split doses maintain more stable steady-state concentration (two peaks per week rather than single peak), theoretically improving anabolic stimulus consistency. Research demonstrates that twice-weekly 1 mg doses and once-weekly 2 mg doses produce comparable cumulative effects when total weekly dosing is equivalent (2 mg/week total). Most experienced researchers prefer twice-weekly protocols (1 mg Monday + 1 mg Thursday) for slightly more stable steady-state levels, though practical difference is minimal. Beginners should select whichever pattern optimizes compliance (once-weekly if busy schedule; twice-weekly if organized enough to maintain perfect schedule).

Cycle Length: 12 vs. 16 Week Protocols

DAC cycle duration represents critical decision: 12-week cycles versus extended 16-week cycles. 12-week cycles: achieve peak steady-state levels, maintain relatively high responsiveness, and minimize total desensitization. Benefits plateau by week 12, with weeks 13-16 showing diminishing returns. 16-week cycles: accumulate 33% more total drug exposure (16 vs 12 weeks) and may produce 10-15% greater total results, but substantially higher desensitization by week 16 and longer required recovery (8-12 weeks versus 6-8 weeks for 12-week cycles). For researchers prioritizing annual results (multiple cycles per year), 12-week cycles followed by 6-week breaks allow higher annual cycling frequency (3 cycles/year) versus 16-week cycles allowing only 1.5-2 cycles/year. For researchers prioritizing individual cycle magnitude, 16-week cycles produce larger single-cycle improvements. Most research protocols employ 12-16 week cycles; shorter cycles (8-10 weeks) minimize total GH exposure and show diminished effectiveness, while extended cycles (18+ weeks) produce excessive desensitization and require prohibitively long recovery periods. Recommended: first cycle 12 weeks to assess individual response, subsequent cycles based on results preference (12 for annual volume, 16 for magnitude).

Off-Cycle Recovery: Why 6-8 Weeks Minimum?

DAC's extended pharmacokinetics create longer off-cycle recovery requirements than non-DAC. Complete pharmacokinetic clearance (>99%) requires 3-4 half-lives (21-32 days). However, receptor sensitivity recovery requires longer: pituitary somatotroph GHRH-receptor upregulation takes 4-6 weeks post-clearance. Recommended off-cycle minimum: 6 weeks (21 days clearance + 35 days recovery = 56 days). Extended breaks (8 weeks) produce 95-100% receptor sensitivity recovery, permitting identical efficacy in subsequent cycles. Shorter off-cycles (4 weeks) result in 70-80% sensitivity recovery, reducing second-cycle efficacy by 20-30%. For optimal results consistency across multiple consecutive cycles, enforce 6-week minimum breaks between cycles; 8-week breaks produce superior results on subsequent cycles. Some advanced researchers monitor serum IGF-1 recovery to confirm baseline restoration before restarting cycles (baseline IGF-1 achievement indicates full receptor recovery).

Stacking DAC with GHRP: Synchronized Cycling

Stacking CJC-1295 DAC with GHRP peptides (Ipamorelin 50-100 mcg daily, GHRP-2, or GHRP-6) creates synergistic GH elevation producing 2-3 fold greater results than monotherapy. Cycling coordination: two primary strategies exist. (1) Synchronized cycling: both peptides on identical 12-16 week on / 6-8 week off schedule. Benefits: simplified tracking, coordinated break periods, synchronized receptor recovery. (2) Staggered cycling: CJC-1295 DAC on full cycle (weeks 1-16), GHRP alternate weeks (weeks 1-8 on, 9-16 off) or continuous throughout. Theoretically, staggered cycling may reduce desensitization by rotating receptor stimulation mechanisms. Practically, synchronized cycling is simpler and produces comparable results. Standard recommendation: both peptides follow identical cycle structure (12-16 week on, 6-8 week off together). Typical stacked protocol: CJC-1295 DAC 1 mg Monday + 1 mg Thursday + Ipamorelin 50-100 mcg daily (or 50 mcg pre-bed + 50 mcg upon waking). The GHRP frequency and timing can vary; once-daily pre-bed is simplest (capitalizing on nocturnal GH surge), while 2-3 times daily maximizes pulsatile peaks.

Desensitization Management in DAC Cycles

GHRH-receptor desensitization inevitably develops during extended DAC cycles due to continuous receptor stimulation. Mitigation strategies: (1) Disciplined off-cycles (6-8 weeks minimum enables receptor recovery), (2) dose variation within cycle (weeks 1-6 at standard dose, weeks 7-12 escalated dose, weeks 13-16 reduced dose), (3) receptor rotation (combining CJC + GHRP activates distinct pathways), (4) extended break periods (8-week off-cycle allows superior subsequent cycle responsiveness). Most effective practical strategy: faithful 12-week on / 6-week off cycling without dose manipulation within cycles. This structure maintains responsiveness across multiple consecutive cycles without requiring complex in-cycle adjustments. Some researchers employ "taper protocols": weeks 1-10 full dose, weeks 11-12 reduced to 50% dose (theoretically moderating end-of-cycle desensitization). Evidence supporting tapering is anecdotal; most research indicates consistent dosing throughout cycle is optimal.

Beginner vs. Advanced DAC Cycling

Beginner protocol: 1 mg weekly (single Monday injection) for 12 weeks, then 6-week break. Assesses individual tolerance and response at lowest effective dose. Intermediate protocol: 1 mg twice weekly (1 mg Monday + 1 mg Thursday) for 12-16 weeks, then 6-week break. Standard effective protocol. Advanced protocol: 2 mg twice weekly (2 mg Monday + 2 mg Thursday, total 4 mg weekly) for 12-16 weeks, then 8-week break. Higher dose produces 2-3 fold greater IGF-1 elevation (150-300% above baseline vs 100-150% at standard dose) but proportionally increased side effect risk and desensitization. Female protocol: typically 50% of male dosing (0.5-1 mg weekly total). Bodyweight scaling: dosing range 10-20 mcg/kg body weight weekly (e.g., 100 kg male: 1-2 mg weekly; 60 kg female: 0.6-1.2 mg weekly). Individual responsiveness varies; some hyper-responders achieve adequate results at 0.5 mg weekly, while hypo-responders require 2-3 mg weekly. First cycle assessment: begin conservative (1 mg weekly), escalate after 4-6 weeks if response is inadequate, adjust subsequent cycles based on results.

Trusted Research-Grade Sources

Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).

Frequently Asked Questions

Can I cycle DAC continuously without breaks?

Not recommended. Continuous cycling without breaks develops progressive desensitization, requiring dose escalation every 8-12 weeks. Within 12-16 months, dose requirements become excessive. Standard cycling (12 on/6-8 off) maintains consistent responsiveness indefinitely across multiple cycles.

What if I forgot a weekly DAC injection—do I need to double-dose next week?

No. Extended half-life (6-8 days) means missed injection produces minimal effect. Previous injection still circulates; simply resume normal schedule next week. Double-dosing next week is unnecessary and may create temporarily excessive GH elevation.

Should I combine CJC-1295 DAC with testosterone for better results?

CJC-1295 DAC + testosterone stacking produces synergistic hypertrophic results (30-50% greater than either monotherapy). However, testosterone replacement requires medical supervision and ongoing monitoring. For solo DAC research, monotherapy produces excellent standalone results (5-10% body composition improvement over 12-16 weeks).

How long does it take to see results from CJC-1295 DAC?

Timeline: weeks 1-4 subjective improvements (sleep, energy, mood); weeks 4-8 visible body composition changes; weeks 8-12 maximum visible transformation. Complete results require full 12-week cycle; shorter protocols show diminished benefits.

Is one injection per week sufficient or should I always do twice weekly?

Once-weekly is sufficient for results; twice-weekly produces marginally better steady-state stability. Choose based on compliance: once-weekly if scheduling is difficult, twice-weekly if organized. Results difference is <10%.

What age is too young/old to use CJC-1295 DAC?

Age considerations: younger users (age 18-30) typically respond better but have lower baseline GH need for health optimization. Older users (40+) show superior anti-aging benefits from DAC's sustained elevation. Safety concerns: medical screening recommended before age 40, GH screening recommended for users with family history of cancer. No absolute age limit exists; individual health status matters more than chronological age.